Cargando…
TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines
BACKGROUND: The nerve growth factor (NGF) receptor tyrosine-kinase TrkA is a well-known determinant of the melanocytic lineage, through modulation of the MAPK and AKT cascades. While TrkA gene is frequently rearranged in cancers, its involvement in malignant melanoma (MM) development is still unclea...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619539/ https://www.ncbi.nlm.nih.gov/pubmed/26496938 http://dx.doi.org/10.1186/s12885-015-1791-y |
_version_ | 1782397126103269376 |
---|---|
author | Pasini, Luigi Re, Angela Tebaldi, Toma Ricci, Gianluca Boi, Sebastiana Adami, Valentina Barbareschi, Mattia Quattrone, Alessandro |
author_facet | Pasini, Luigi Re, Angela Tebaldi, Toma Ricci, Gianluca Boi, Sebastiana Adami, Valentina Barbareschi, Mattia Quattrone, Alessandro |
author_sort | Pasini, Luigi |
collection | PubMed |
description | BACKGROUND: The nerve growth factor (NGF) receptor tyrosine-kinase TrkA is a well-known determinant of the melanocytic lineage, through modulation of the MAPK and AKT cascades. While TrkA gene is frequently rearranged in cancers, its involvement in malignant melanoma (MM) development is still unclear. METHODS: We analyzed a dataset of primary cutaneous MM (n = 31) by array comparative genomic hybridization (aCGH), to identify genomic amplifications associated with tumor progression. The analysis was validated by genomic quantitative PCR (qPCR) on an extended set of cases (n = 64) and the results were correlated with the clinical outcome. To investigate TrkA molecular pathways and cellular function, we generated inducible activation of the NGF-TrkA signaling in human MM cell lines. RESULTS: We identified amplification of 1q23.1, where the TrkA locus resides, as a candidate hotspot implicated in the progression of MM. Across 40 amplicons detected, segmental amplification of 1q23.1 showed the strongest association with tumor thickness. By validation of the analysis, TrkA gene amplification emerged as a frequent event in primary melanomas (50 % of patients), and correlated with worse clinical outcome. However, experiments in cell lines revealed that induction of the NGF-TrkA signaling produced a phenotype of dramatic suppression of cell proliferation through inhibition of cell division and pronounced intracellular vacuolization, in a way straightly dependent on NGF activation of TrkA. These events were triggered via MAPK activity but not via AKT, and involved p21(cip1) protein increase, compatibly with a mechanism of oncogene-induced growth arrest. CONCLUSIONS: Taken together, our findings point to TrkA as a candidate oncogene in MM and support a model in which the NGF-TrkA-MAPK pathway may mediate a trade-off between neoplastic transformation and adaptive anti-proliferative response. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1791-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4619539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46195392015-10-26 TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines Pasini, Luigi Re, Angela Tebaldi, Toma Ricci, Gianluca Boi, Sebastiana Adami, Valentina Barbareschi, Mattia Quattrone, Alessandro BMC Cancer Research Article BACKGROUND: The nerve growth factor (NGF) receptor tyrosine-kinase TrkA is a well-known determinant of the melanocytic lineage, through modulation of the MAPK and AKT cascades. While TrkA gene is frequently rearranged in cancers, its involvement in malignant melanoma (MM) development is still unclear. METHODS: We analyzed a dataset of primary cutaneous MM (n = 31) by array comparative genomic hybridization (aCGH), to identify genomic amplifications associated with tumor progression. The analysis was validated by genomic quantitative PCR (qPCR) on an extended set of cases (n = 64) and the results were correlated with the clinical outcome. To investigate TrkA molecular pathways and cellular function, we generated inducible activation of the NGF-TrkA signaling in human MM cell lines. RESULTS: We identified amplification of 1q23.1, where the TrkA locus resides, as a candidate hotspot implicated in the progression of MM. Across 40 amplicons detected, segmental amplification of 1q23.1 showed the strongest association with tumor thickness. By validation of the analysis, TrkA gene amplification emerged as a frequent event in primary melanomas (50 % of patients), and correlated with worse clinical outcome. However, experiments in cell lines revealed that induction of the NGF-TrkA signaling produced a phenotype of dramatic suppression of cell proliferation through inhibition of cell division and pronounced intracellular vacuolization, in a way straightly dependent on NGF activation of TrkA. These events were triggered via MAPK activity but not via AKT, and involved p21(cip1) protein increase, compatibly with a mechanism of oncogene-induced growth arrest. CONCLUSIONS: Taken together, our findings point to TrkA as a candidate oncogene in MM and support a model in which the NGF-TrkA-MAPK pathway may mediate a trade-off between neoplastic transformation and adaptive anti-proliferative response. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1791-y) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-24 /pmc/articles/PMC4619539/ /pubmed/26496938 http://dx.doi.org/10.1186/s12885-015-1791-y Text en © Pasini et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Pasini, Luigi Re, Angela Tebaldi, Toma Ricci, Gianluca Boi, Sebastiana Adami, Valentina Barbareschi, Mattia Quattrone, Alessandro TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines |
title | TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines |
title_full | TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines |
title_fullStr | TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines |
title_full_unstemmed | TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines |
title_short | TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines |
title_sort | trka is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619539/ https://www.ncbi.nlm.nih.gov/pubmed/26496938 http://dx.doi.org/10.1186/s12885-015-1791-y |
work_keys_str_mv | AT pasiniluigi trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines AT reangela trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines AT tebalditoma trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines AT riccigianluca trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines AT boisebastiana trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines AT adamivalentina trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines AT barbareschimattia trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines AT quattronealessandro trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines |